-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VxVP4xRQWt5F2Xn3gXMlnkT1uzkq3JMcy/4RP+zS6va6Vy616GXFHU/hD70+IF1J 7Uv/A3sUD6xa6fbVeIKIXg== 0001454982-10-000030.txt : 20100204 0001454982-10-000030.hdr.sgml : 20100204 20100204192102 ACCESSION NUMBER: 0001454982-10-000030 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100202 FILED AS OF DATE: 20100204 DATE AS OF CHANGE: 20100204 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ROWLAND LLOYD A CENTRAL INDEX KEY: 0001236395 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19700 FILM NUMBER: 10575345 MAIL ADDRESS: STREET 1: AMYLIN PHARMACEUTICALS INC STREET 2: 9360 TOWNE CENTRE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMYLIN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000881464 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330266089 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6195522200 MAIL ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0303 4 2010-02-02 0 0000881464 AMYLIN PHARMACEUTICALS INC AMLN 0001236395 ROWLAND LLOYD A 9360 TOWNE CENTRE DR SAN DIEGO CA 92121 0 1 0 1 VP Governance Compliance & Co VP Governance Compliance & Co Common Stock 2010-02-03 4 A 0 412 17.83 A 26684 D Common Stock 2010-02-03 4 A 0 1360 0 A 4815 I by ESOP Incentive Stock Option (right to buy) 18.01 2010-02-02 4 A 0 7081 0 A 2017-02-02 Common Stock 7081 7081 D Non-Qualified Stock Option (right to buy) 18.01 2010-02-02 4 A 0 12919 0 A 2017-02-02 Common Stock 12919 12919 D Represents shares acquired pursuant to the Company's 401(k) plan. These shares fully vest four years from the date of the reporting person's participation in the ESOP in four equal annual installments and are generally distributed upon termination of employment. 25% of shares vest one year from date of grant and the remainder vest monthly over the next three years becoming fully vested four years from date of grant. By: /s/James R. Oehler, Attorney-in-Fact For: Lloyd A. Rowland 2010-02-04 -----END PRIVACY-ENHANCED MESSAGE-----